6NOVEMBER - 2021TECH OUTLOOKEditorialStacey Smith Editor-in-Chiefeditor@pharmatechoutlook.comSeveral life sciences companies are finding themselves thrust into a digital-first scenario due to the risks presented by the pandemic. As a result, they are modernising analytics to change engagement strategies with healthcare providers and keep clinical trials operating in a decentralised model. This transformation is bound to accelerate through the rest of 2021.Besides, technologies like AI and machine learning are poised to offer new ways of analysing and processing data, allowing the pharmaceutical industry's use of analytics to step up a gear. Applying AI to data will help reveal hidden patterns from data sets in a way that isn't possible when an individual has to click through 100 bricks or 200 practices and look at every pack or product prescribed to try and decide if something has happened. There is a wealth of different hidden patterns in the data that the human eye can't identify, while the machine won't rest until they are found. Technologies like BI tools, on the other hand, will provide key metrics for pharma companies to track sales performance over time, whether through market share, contact rates, or other endpoints.Alongside, the demand for analytical testing support is growing within the pharmaceutical industry as companies seek to maximise the use of internal resources for highly complex and proprietary activities. In this edition of Pharma Tech Outlook Europe, we bring you the story of some of the leading analytical service providers in the European region that deliver the best outcomes for clients. The magazine also offers a combination of thought leadership articles from subject matter experts and exclusive insights from CIOs and CXOs. We hope this edition will provide you with the right assistance in choosing the analytical services providers that best fits your requirements.Let us know your thoughts!Modernisation of Pharma Analytics in a Post-COVID WorldTECH OUTLOOKTECH OUTLOOKCopyright © 2021 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.NOVEMBER - 01 - 2021, Vol 07 - Issue 011 (ISSN 2644-2787) Published by ValleyMedia, Inc. To subscribe to Pharma Tech OutlookVisit www.pharmatechoutlook.com *Some of the Insights are based on the interviews with respective CIOs and CXOs to our editorial staffEditor-in-ChiefStacey SmithVisualizerJaxon JaseEditorial StaffAaron Pierce Ava GarciaJenna VegasCarolynn Walters Justin SmithPaul BarberSalesBrian Thomasbrian@pharmatechoutlook.comPhone: 510.556.2402sales@pharmatechoutlook.comeditor@pharmatechoutlook.commarketing@pharmatechoutlook.comEmail:David Parker
< Page 5 | Page 7 >